首页 | 本学科首页   官方微博 | 高级检索  
     

异甘草酸镁治疗肝癌动脉栓塞化疗肝损伤的临床研究
引用本文:陈玉强,洪节约,张雅雅,邱国钦,郭春华. 异甘草酸镁治疗肝癌动脉栓塞化疗肝损伤的临床研究[J]. 江苏临床医学杂志, 2010, 0(9): 15-17,25
作者姓名:陈玉强  洪节约  张雅雅  邱国钦  郭春华
作者单位:中国人民解放军第一七四医院,福建厦门361003
摘    要:目的观察异甘草酸镁注射液对于肝癌介入栓塞化疗术(TACE)后肝损伤的临床治疗效果。方法选取本院中晚期原发性肝癌行TACE患者105例,随机分为实验组(n=65)和对照组(n=40)。实验组用异甘草酸镁注射液护肝药物治疗,对照组用甘草酸二胺注射液护肝药物治疗,2组均在TACE术前3 d~术后7 d用药,并在TACE术前及术后2 d7、d抽血检测肝功能;同时记录2组患者TACE术后不良反应的发生率。结果 TACE术后2 d 2组患者总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)等指标均高于术前(P〈0.05);术后7 d实验组ALT、AST与术前比较无显著性差异(P〉0.05),而术后7 d对照组ALT、AST仍高于术前(P〈0.05);2组方案对TACE术后肝细胞合成指标降低均无明显改善作用(P〉0.05),实验组术后不良反应发生率明显低于对照组(P〈0.05)。结论异甘草酸镁对TACE引起的患者肝功能损害有迅速、明显的保护作用,并可减轻TACE不良反应。

关 键 词:异甘草酸镁  肝癌  介入栓塞化疗术(TACE)  肝损伤

A clinical research of magnesium isoglycyrrhizinate trerapy for liver lesion in transcatheter arterial chemoembolization
CHEN Yu-qiang,HONG Jie-yue,ZHANG Ya-ya,QIU Guo-qin,GUO Chun-hua. A clinical research of magnesium isoglycyrrhizinate trerapy for liver lesion in transcatheter arterial chemoembolization[J]. Journal of Jiangsu Clinical Medicine, 2010, 0(9): 15-17,25
Authors:CHEN Yu-qiang  HONG Jie-yue  ZHANG Ya-ya  QIU Guo-qin  GUO Chun-hua
Affiliation:(No.174 Hospital of PLA,Xiamen,Fujian,361003)
Abstract:Objective To explore the clinic effect of Magnesium isoglycyrrhizinate on the patients with primary hepatic carcinoma after transcatheter arterial chemoembolization(TACE).Methods 105 cases with malignant tumor complicated with liver lesion induced by TACE were randomly divided to receive magnesium isoglycyrrhizinate therapy(treatment group) or diammonium glycyrrhizinate injection(control group) with 150 mg iv gtt qd from Preoperative 3 days to the 7th day after TACE operation.The incidences of the adverse effect after TACE operation were memorized.Results The levels of TBIL,ALT and AST on the 2nd day after TACE operation were higher than those before TACE operation in the two groups(P0.05).The levels of ALT and AST on the 7th day after TACE operation were revivaled in the therapy group(P0.05). But the levels of ALT and AST in the control group on the 7th day were higher than those before TACE operation(P0.05).The index of the synthesis ability of hepatocyte was not improved in the therapy group(P0.05).The incidence of the adverse effect in the therapy group was lower than that in the control group(P0.05).Conclusion Magnesium isoglycurrhizinate can distinctly protect the liver function of the patients with primary hepatic carcinoma after TACE operation and prevent the adverse effect.
Keywords:magnesium isoglycyrrhizinate  transcatheter arterial chemoembolization(TACE)  liver lesion
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号